Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12618000781246
ACTRN12618000781246
Completed
Phase 4

Inhaled corticosteroids for treating active lung disease in survivors of preterm birth

Telethon Kids Institute0 sites214 target enrollmentMay 9, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Telethon Kids Institute
Enrollment
214
Status
Completed
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 9, 2018
End Date
May 5, 2022
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Preterm\-born participants: Children aged 6\-12 years who were born at less than or equal to 32 weeks gestation,
  • •Healthy volunteers: Children aged 6\-12 years who were born \>37 weeks gestation who have no recurrent respiratory symptoms.

Exclusion Criteria

  • •Severe congenital abnormalities
  • •Severe cardiopulmonary defects
  • •Severe neurodevelopmental impairment
  • •Glucocorticoid use within the past 3 months

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Corticosteroids for patients with acute respiratory distress syndrome; systematic review and meta-analysis.Acute respiratory distress syndrome
JPRN-UMIN000041007JA General Hospital.
Active, not recruiting
Phase 1
Treating COVID-19 infections with inhaled corticosteroidsCOVID 19Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2020-001889-10-GBniversity of Oxford, Clinical Trials and Research Governance478
Recruiting
Phase 1
Effect of Corton on olfactory dysfunction in COVID-19 patients
IRCT20200522047542N1Mashhad University of Medical Sciences70
Recruiting
Not Applicable
Effect of inhaled corticosteroid therapy in pulmonary sarcoidosis patients who manifest airflow limitatio
JPRN-UMIN000013831Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan40
Active, not recruiting
Phase 1
treatment with inhaled corticoids in patients with covid-19 and pneumoniaCOVID19MedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2020-001616-18-ESFundació Clinic per a la Recerca Biomèdica300